您好,欢迎访问三七文档
当前位置:首页 > 商业/管理/HR > 咨询培训 > 高血压患者预防脑卒中阿司匹林服药依从性的研究进展_杨正义
4912014ChinJNurs,July2014,Vol.49,No.720147497,,10mmHg(1mmHg=0.133kPa),49%,5mmHg,46%[1]。54%[2],[3],5.94。,,,。:。,。,,。12060,Bunzel[4]、。2080,、、、[5]。“”,[6]。WHO,:,、、[7]。。,,,[8]。2,。[9]、(MEMS)[10]、[11];。,。Morisky(MAQ):4,,。Morisky[12]2008MAQ,,8(MMAS-8),,MAQ。MAQMMAS-8[13-14]。:(MASES)[15](SEAMS)[16]。,。MASES,26;SEAMS,13。MASES、SEAMS,。,、,。3,、,DOI:10.3761/j.issn.0254-1769.2014.07.025:510089(,);():,E-mail:wanlh@mail.sysu.edu.cn:,(),E-mail:yangzhengyi1990@126.com2013-09-18杨正义万丽红简丽霞【】阿司匹林;脑血管意外;病人依从;一级预防【Keywords】Aspirin;CerebrovascularAccident;PatientCompliance;PrimaryPrevention867CMYK4912014ChinJNurs,July2014,Vol.49,No.720147497[17]。2070,30400:[18]。Ridker[19](WHS):17%,24%,24%27%。Berger[20],17%。:2003(JNC)7[21],;2006(AHA)/(ASA)[22],、,;2008(ASH)[23]75~162mg/d。,2005《》2007《》。2005[24]:(150/90mmHg)1,。,[25],,。,,≥50,106%~10%,。,。4,[26],。:,,。[27],。[28],50.25%(75mg/d)。[29-30],100mg/d(75~150mg),75mg/d。AHA/ASA75~150mg/d,。,。[31]1325,23.55%,39.70%。[28]、、、9000,19.93%。;,,。[32],4.15%。:,;;。5,、、,。,868CMYK4912014ChinJNurs,July2014,Vol.49,No.7201474971.5[33],。[34],74.5%,43.62%,47.69%。,,,。[35]:、、。[36],、、、、。[37],、、、、,。,,。,,[38]。[39],,27.0%,24.8%,。:,,,,[40]。。,,[41]。[42],。[43]:,,、,。[44],。,、。6,,,。。,。,;,;,。,。--,,,,。[1].2010[J].,2011,39(7):579-616.[2]LawesCm.VanderHoomSRA.Globalburdenofblood-pressurerelateddisease,2001[J].Lancet,2008,371(9623):1513-1518.[3],,,.[J].,2012,20(3):287-289.[4]BunzelB,Laederach-HofmannK.Solidorgantransplantation:aretherepredictorsforposttransplantnoncompliance?Aliter-atureoverview[J].Transplantation,2000,70(5):711-716.[5],,,.1979~2003[J].,2004,13(5):263-265.[6],,.[J].,2009,26(3):36-37.[7]DeGeestS,SabateE.Adherencetolong-termtherapies:evi-denceforaction[J].EurJCardiovascNurs,2003,2(4):323.[8]HillM,MillerN,DegeestS.ASHpositionpaper:adherenceandpersistencewithtakingmedicationtocontrolhighbloodpres-sure[J].JClinHypertens(Greenwich),2010,12(10):757-764.[9]BalkrishnanR,JayawantSS.Medicationadherenceresearchinpopulations:measurementissuesandotherchallenges[J].ClinTher,2007,29(6):1180-1183.[10]MallionJM,Dutrey-DupagneC,VaurL,etal.Benefitsofelectronicpillboxesinevaluatingtreatmentcomplianceofpatientswithmildtomoderatehypertension[J].JHypertens,1996,14(1):137-144.[11]Krousel-WoodM,ThomasS,MuntnerP,etal.Medicationad-herence:akeyfactorinachievingbloodpressurecontrolandgoodclinicaloutcomesinhypertensivepatients[J].CurrOpin869CMYK4912014ChinJNurs,July2014,Vol.49,No.720147497Cardiol,2004,19(4):357-362.[12]MoriskyDE,GreenLW,LevineDM.Concurrentandpredic-tivevalidityofaself-reportedmeasureofmedicationadher-ence.[J].1986,24(1):67-74.[13]HoltEW,MuntnerP,JoyceCJ,etal.Health-relatedqualityoflifeandantihypertensivemedicationadherenceamongolderadults[J].AgeAgeing,2010,39(4):481-487.[14]AmadoGE,PujolRE,PachecoHV,etal.Knowledgeandadherencetoantihypertensivetherapyinprimarycare:re-sultsofarandomizedtrial[J].GacSanit,2011,25(1):62-67.[15]OgedegbeG,MancusoCA,AllegranteJP,etal.Developmentandevaluationofamedicationadherenceself-efficacyscaleinhypertensiveAfrican-Americanpatients[J].JClinEpi-demiol,2003,56(6):520-529.[16]RisserJ,JacobsonTA,KripalaniS.Developmentandpsy-chometricevaluationoftheSelf-efficacyforAppropriateMedicationUseScale(SEAMS)inlow-literacypatientswithchronicdisease[J].JNursMeas,2007,15(3):203-219.[17]BatesER,WcL.Controversiesinanti-platelettherapyforpatientswithcardiovasculardisease[J].Circulation,2005,111(17):267-271.[18]GasparyanAY,WatsonT,LipGY.Theroleofaspirinincar-diovascularprevention:implicationsofaspirinresistance[J].JAmCollCardiol,2008,51(19):1829-1843.[19]RidkerPM,CookNR,LeeIM,etal.Arandomizedtrialoflow-doseaspirinintheprimarypreventionofcardiovasculardiseaseinwomen[J].NEnglJMed,2005,352(13):1293-1304.[20]BergerJS,RoncaglioniMC,AvanziniF,etal.Aspirinfortheprimarypreventionofcardiovasculareventsinwomenandmen:asex-specificmeta-analysisofrandomizedcontrolledtrials[J].JAMA,2006,295(3):306-313.[21]ChobanianA,BakrisG,BlackH,etal.Theseventhreportofthejointnationalcommitteeonprevention,detection,evalua-tionandtreatmentofhighbloodpressure:TheJNC7report[J].JAmMedAssoc,2003,289(19):2560-2572.[22].2006[J].,2007,15(3):241-244.[23]BakrisGL,SowersJR.ASHpositionpaper:treatmentofhy-pertensioninpatientswithdiabetes-anupdate[J].JClinHyper-tens(Greenwich),2008,10(9):707-715.[24].:(2005)[J].,2006,34(3):281-284.[25].2430[J].,2003,11(5):446-450.[26]BaigentC,BlackwellL,CollinsR,etal.Aspirininthepri-maryandsecondarypreventionofvasculardisease:collabo-rativemeta-analysisofindividualparticipantdatafromran-domisedtrials[J].Lancet,2009,373(9678):1849-1860.[27],,,.[J].:,2008(8):9-12.[28],,,.[J].,2011,3(1):22-26.[29]BenjaminEJ,LevyD.Whyisleftventricularhypertrophy60predictiveofmorbidityandmortality[J].AmJMedSet,1999,317(3):168-175.[30]CollaborationAT.Collaborativemeta-analysisofrandomizedtrialsofanti-platelettherapyforpreventionofdeathmyocar-dial’infarctionandstrokeinhighriskpatients[J].BMJ,2002,324(7329):71-86.[31],,.[J].,2012,20(4):492-493.[32],,.541[J].,2010,36(10):594-597.[33].2010[J].,2010,43(2):154-160.[34],,,.[J].,2012(2):103-104.[35]HigginsN,ReganC.Asy
本文标题:高血压患者预防脑卒中阿司匹林服药依从性的研究进展_杨正义
链接地址:https://www.777doc.com/doc-3606131 .html